Abstract:Background: Prostate cancer is a complex and heterogeneous disease with multiple tumor foci, each potentially harboring distinct driver molecular aberrations. This complexity poses challenges to effective management. We took an innovative approach to gain a comprehensive understanding of the genetic underpinnings of each tumor focus and avoid overlooking more minor yet clinically significant foci. Instead of relying solely on a systematic sampling of dominant foci, we conducted molecular analysis on whole-mount radical prostatectomy specimens. Our study aimed to find distinct molecular subsets of prostate cancer and assess their correlation with clinical outcomes, focusing on Caucasians (CA) and African Americans (AA). Method: We randomly selected 2201 whole-mount radical prostatectomy cases, with 1207 (54.8%) from CA and 994 (45.1%) from AA patients evaluated for a 5-year biochemical recurrence-free survival rate (BCR). Of these 2201 cases, 834 (463 -56% were from CA and 371 -44% from AA patients) were subjected to molecular analysis using dual immunohistochemistry (IHC) for ERG and SPINK1, along with dual RNA in-situ hybridization (RNA-ISH) for ETV1 and ETV4 to evaluate tumor molecular heterogeneity on whole-mount specimens. The Chi-squared test examined racial disparities in aberrant oncogene expression. To assess BCR-free survival, we employed the Kaplan-Meier method and Cox-PH models for patients with distinct molecular subsets of prostate cancer. Additionally, Gleason Grade groups of prostate biopsies were summarized using a spaghetti plot and compared using linear mixed models. Results: Analysis of the 2201 cases revealed that AA with localized prostate cancer behaved differently with better 5-year BCR-free survival than CA after radical prostatectomy (AA: 0.82, 95% CI 0.80-0.85; CA: 0.71, 95% CI 0.68-0.75; p<.001). Molecular profiling of whole-mount specimens from 834 cases revealed that 16.4%, 58.4%, 21.7%, and 3.5% of patients with localized prostate cancer expressed none, one, two, and three of the four oncogenes, respectively. This finding identified new molecular subsets of prostate cancer with more than one driver mutation in a mutually exclusive manner within the multifocal disease. ERG and SPINK1 expression showed a negative correlation (p<.001). Notably, AA patients exhibited a lower incidence of ERG (38.8% vs. 60.3%) but a higher incidence of SPINK1 (63.3% vs. 35.6%) than CA patients. The incidences of ETV1 (9.4% vs. 9.3%) and ETV4 (4.6% vs. 3.9%) were not statistically significant between the two racial groups. However, significantly, ETV1 expression was associated with worse BCR-free survival in CA patients (hazard ratio [HR]=2.36, 95% CI 1.22-4.57, p=.02), while ETV4 expression was linked to worse BCR-free survival in AA patients (HR=2.65, 95% CI 1.15-6.09, p=.02). Moreover, ETV4 expression was associated with regional lymph node metastasis in AA patients (odds ratio [OR]=5.14, 95% CI 1.3-17.4, p=.01) but not in CA patients (OR=0.60, 95% CI 0.03-3.17, p=.63) at the time of radical prostatectomy. Additionally, in patients who underwent multiple biopsies before radical prostatectomy, the Gleason Grade group increased over time in AA patients (0.25 per year, p<.001) but remained unchanged in CA patients. ERG expression was associated with a lower Gleason Grade group (-0.20, p=.03), while ETV4 expression was linked to a higher Gleason Grade (0.54, p=.01). Conclusions: Our study reveals that AA with localized prostate cancer behaves differently and has better BCR-free survival than CA after radical prostatectomy, even after adjusting for known prognostic factors. Identification of new molecular subsets of prostate cancer with more than one ETS gene fusion within a multifocal prostate shows significant molecular heterogeneity between localized prostate cancer in CA and AA patients. Importantly, given the association of ETV1 and ETV4 expression with worse BCR-free survival in CA and AA, respectively, ETV1 and ETV4 emerge as potential prognostic markers, offering insights for clinical practice to predict prostate cancer recurrence after radical prostatectomy. Identification of new molecular subsets of prostate cancer with more than one ETS gene fusion and SPINK1 in a mutually exclusive pattern indicates the clonal origin of independent tumor foci, which is a rare and unique phenomenon in prostate cancer hitherto unidentified.

Ductal Adenocarcinoma of the Prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing

Molecular Characterization of Clinically Defined Aggressive Variant Prostate Cancer (avpca) in Prospectively Collected Tissues and Corresponding Patient Derived Xenografts (PDX).

AVPC Molecular Signature Supplementary Figures from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients

Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes

Mixed Adenosquamous Cell Carcinoma of the Prostate with Paired Sequencing on the Primary and Liver Metastasis

Integrative Clinical Genomics of Advanced Prostate Cancer

Circulating Tumor DNA-targeted Sequencing to Reveal Germline and Somatic Alterations That Can Guide Decision-Making in Metastatic Castration-Resistant Prostate Cancer.

Abstract P008: Native Cell-Free DNA sequence analysis reliably infers epigenetically diverse subtypes of prostate cancer

Ductal adenocarcinoma of the prostate: clinical analysis of 8 cases

BRCA2 , ATM , and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression

Clinical implications of genomic alterations in metastatic prostate cancer

Advanced Prostatic Ductal Carcinoma in a Patient with a Long Survival Time Following a Total Pelvis Exenteration: A Case Report.

Characterizing longitudinal molecular changes in ctDNA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Unveiling Prostate Cancer's Molecular Tapestry: Ethnic Disparities and Prognostic Insights from Whole-Mount Prostatectomy Tissue Analysis

Construction and validation of a prognostic nomogram for ductal adenocarcinoma of the prostate: A population-based study

Utility and Clinical Application of Circulating Tumor DNA (ctDNA) in Advanced Prostate Cancer

Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.

Extrachromosomal circular DNAs in prostate adenocarcinoma: global characterizations and a novel prediction model